ÂÜÀòÂÒÂ×

Mitchell Chan is the current Director at Avalo Therapeutics. Prior to this, they were the Chief Financial Officer at Viela Bio from September 2018 to March 2021. From September 2015 to September 2018, Chan was the Director of Investor Relations - North America at AstraZeneca. Mitchell also worked at Roche from August 2011 to July 2012 as part of the Mergers & Acquisitions team. From August 2012 to August 2015, Chan was in Commercial Finance at Genentech. Mitchell began their career at Genentech in June 2010 as part of the Global Product Development Finance team before moving to BioDiscovery Toronto in January 2006 where they worked in Venture Capital & Business Development.

Mitchell Chan has a Bachelor of Science from the University of Toronto in Biochemistry, a Master of Science from the University of Toronto in Medical Biophysics, and a Master of Business Administration from the University of Toronto - Rotman School of Management in Investment Banking. Mitchell also has a Strategic Finance Executive Program from the Haas School of Business at the University of California, Berkeley and a Strategic Decision and Risk Management Certificate from The Wharton School.